A significant milestone has been reached in the fight against paediatric HIV with the enrolment of the first participants in the UNIVERSAL1 trial. This achievement is a testament to the tremendous effort and dedication of the site staff in Uganda and Zimbabwe. UNIVERSAL 1 will investigate whether a fixed-dose combination of dolutegravir, emtricitabine, and tenofovir alafenamide, a highly effective and well-tolerated regimen for adults, is as safe and effective for children aged between 28 days and 10 years of age.
Currently, treating children with HIV poses significant challenges. Existing treatment options often require complex dosing schedules and multiple medications, making adherence difficult. The lack of age-appropriate formulations further complicates treatment and can lead to suboptimal outcomes.
The enrolment of the first patient marks a crucial step in this ambitious project. Researchers are optimistic that the findings from the UNIVERSAL 1 trial will pave the way for a single, optimized, and simplified treatment option for all children living with HIV, ultimately transforming the landscape of paediatric HIV care.
Congratulations to the site teams on achieving this milestone.
Visit the UNIVERSAL website to learn more about the project